Type II diabetes mellitus (T2DM) is a chronic non-communicable disease due to abnormal insulin actions causing uncontrolled hyperglycaemia. The treatment for T2DM, for instance, metformin and incretin mimetic, mainly focuses on the restoration of insulin sensitivity and secretion. Exendin-4 is a short incretinmimetic peptide consisting of 39 amino acids. It is discovered in the venom of Heloderma suspectum as a full agonist for the glucagon-like peptide 1 (GLP-1) receptor and produces insulinotropic effects. It is more resistant to enzymatic degradation by dipeptidyl-peptidase-4 and has a longer half-life than the endogenous GLP-1; thus, it is further developed as an incretin hormone analogue used to treat T2DM. The helical region of the peptide first interacts with the extracellular N-terminal domain (NTD) of GLP-1 receptor while the C-terminal extension containing the tryptophan cage further enhances its binding affinity. After binding to the NTD of the receptor, it may cause the receptor to switch from its auto-inhibited state of the receptor to its auto-activated state. Exendin-4 enhances the physiological functions of β-cells and the up-regulation of GLP-1 receptors, thus reducing the plasma glucose levels. Moreover, exendin-4 has also been found to ameliorate neuropathy, nephropathy and ventricular remodelling. The therapeutic effects of exendin-4 have also been extrapolated into several clinical trials. Although exendin-4 has a reasonable subcutaneous bioavailability, its half-life is rather short. Therefore, several modifications have been undertaken to improve its pharmacokinetics and insulinotropic potency. This review focuses on the pharmacology of exendin-4 and the structure-function relationships of exendin-4 with GLP-1 receptor. The review also highlights some challenges and future directions in the improvement of exendin-4 as an anti-diabetic drug.
| BACKGROUND
Diabetes is a non-communicable chronic disease due to defective glucose metabolism. Diabetes is generally manifested with uncontrolled hyperglycaemia or continuously elevated blood glucose levels and leads to serious complications especially in vascular diseases. 1 The classification of diabetes is established on the foundation of plasma glucose levels during an oral glucose tolerance test: diabetes mellitus (plasma glucose levels are beyond the limits), impaired glucose tolerance (plasma glucose levels are above the normal range but slightly below the threshold limits) and gestational diabetes. 1 Diabetes mellitus (DM) is further categorised into type I and type II DM. Type I DM (T1DM, formerly known as insulin-dependent DM) is characterised by a deficiency in insulin secretion attributed to destruction of pancreatic β-cells. 2 Type II diabetes mellitus (T2DM, previously known as non-insulin-dependent DM) is associated with an abnormal insulin secretion or chronic insulin resistance, causes the glucose uptake cells to become desensitised towards the insulin action. 2 According to the World Health Organization, diabetes caused 1.6 million deaths and 422 million adults had diabetes in 2015, this number is increasing at an alarming rate. 3 Type II diabetes mellitus accounts for more than 85% of the world diabetes prevalence, rendering it an attentive public health concern. 3 The existing therapeutic options for T2DM are, for example, metformin, insulin secretagogues and incretin mimetic. Metformin is a first-line anti-diabetic agent, which reduces glucose output and restores the sensitisation of tissues to insulin, 4 while incretin mimetic refers to any molecules that mimic the action of endogenous incretin hormone, that is glucagon-like peptide 1 (GLP-1) for the treatment of T2DM. 5 An example of a GLP-1 analogue, exendin-4 was discovered two decades ago from Gila monster venom. In this review, we will discuss the incretin actions and pharmacology of exendin-4 reported so far, the structure-function relationship of exendin-4 with the target of GLP-1 receptors and the challenges of exendin-4 as an anti-diabetic drug.
| DISCOVERY OF EXENDIN-4 AND IDENTIFICATION OF THE CELLULAR TARGET
Gila monster (H. suspectum) is a venomous lizard species natively distributed in the south-western United States and Sonora. The major proteins present in H. suspectum venom are acidic phospholipase A 2 , natriuretic and helokinestatin peptides, kallikrein-like serine protease, type III phospholipase A 2 and neuroendocrine convertase 1 homologue, which very likely convert pro-exendins into mature and active form. 6 It was first discovered that the H. suspectum venom could increase the cAMP levels in pancreatic acinar cells by 50-60 times and inhibited the binding of a vasoactive intestinal peptide (VIP) to its receptor. 7 Radioimmunoassay later proved that the peptides were responsible for blocking binding of the VIP to its receptor on pancreatic acinar cells. In 1992, Dr. John Eng, an endocrinologist, unravelled that these peptides contain N-terminal histidine residues and C-terminal serine residues using a chemical assay. 8 Later, Eng and colleagues 9 reported the first isolation of these peptides from Heloderma venom using reverse-phase C 18 HPLC. The identity of these peptides was then confirmed by mass spectrometry analysis. The overlapping trypsin-digested peptide fragments and direct sequencing of the intact peptides confirmed the identity of these peptides as exendin-3 and exendin-4. As a result, two peptides with histidine residues at position 1 (His1) were isolated from Heloderma venom. Mass spectrometry analysis indicated that exendin-4 has an identical monoisotopic mass to that of exendin-3. Exendin-4 differs from exendin-3 by two residues substitutions (Gly2-Glu3 in place of Ser2-Asp3) and so does its bioactivity. Exendin-3 and exendin-4 are small peptides of 39 amino acids with a carboxyl-terminal serine and an amino-terminal histidine residue. Due to their characteristics, they are categorised as peptide hormones belonging to the glucagon superfamily, which act as pancreatic secretagogues. 9 Both peptides induce cAMP release in pancreatic acinar cells via binding to exendin receptors. Exendin-4 stimulates a monophasic release of cAMP, while exendin-3 causes a biphasic release of cellular cAMP. 8 Besides, exendin-3 stimulates a pancreatic release of amylase by binding to VIP receptors, but exendin-4 does not bind to VIP receptors. Therefore, it does not antagonise the binding of VIP to its receptor and does not stimulate VIP-induced release of enzyme amylase. 9 Due to the distinct features of exendin-4 and exendin-3, it draws researcher's attention to study the interactions between exendin-4 and exendin receptor in mammals.
Various peptide hormones possess sequence similarity to exendin-4, which is a venom analogue of the physiological mammalian hormone glucagon-like peptide 1 (GLP-1). In H. suspectum venom, exendin-4 and GLP-1 are encoded by different tissue-specific genes, making them closely related but somehow distinct from each other. 10 Glucagon-like peptide 1 shows a similar mode of action to that of exendin-4, which involves the elevation of cAMP via the activation adenylyl cyclase signalling cascade without the release of enzyme amylase. 11 It is further proven with an exendin receptor antagonist that exendin-(9-39) NH 2 inhibits the release of cAMP in a proportional level, concluding that GLP-1 is the agonist for exendin receptor. 11 To further validate the identity of exendin receptor, the gene encoded for GLP-1 receptor was isolated from the human pancreatic islet cDNA library and subsequently cloned into Chinese hamsters' fibroblasts. The cloned human GLP-1 receptor was found to bind GLP-1 and induced cAMP releases through adenylyl cyclase second messenger cascade. The similar effects were observed when exendin-4 interacted with same GLP-1 receptor. 12 Based on the findings, it was concluded that exendin receptors were indeed the GLP-1 receptors. The GLP-1 receptors are the cellular targets for exendin-4. Although exendin-4 and GLP-1 only share 50% of sequence similarity, exendin-4 is a full agonist for the GLP-1 receptor on the pancreatic β-cells. It causes a dose-dependent glucose-induced secretion of hormone insulin. 13 To date, exendin-4 has been commercialised into its synthetic form, generically known as exenatide with the trade name Byetta ® (or Bydureon ® ), with an estimated cost of $748-$795 for 1.2 mL pen cartridge (5 mcg/0.02 mL, for subcutaneous injection). Exenatide can be synthesised via solid-phase peptide synthesis. The peptide synthesis begins with deprotection of side-chain protecting groups Fmoc N-(9-fluorenylmethoxycarbonyl) using trifluoroacetic acid as scavengers. This is followed by activation of successive amino acids, coupling reaction and cleavage of peptide chain from resin.
Exendin-4 and GLP-1 are both peptide agonists for GLP-1 receptors. Although both exendin-4 and GLP-1 share structural similarity, the primary sequence and receptorbinding properties of GLP-1 are different from that of exendin-4. 15 Exendin-4 exhibits higher binding affinity (Kd = 6 nmol/L) than GLP-1 peptide (Kd value >500 nm) by 400 times towards a fully isolated NTD preparation of the receptor, as measured in a radioligand binding assay. 16, 17 Exendin-4 shows 53% homology with human GLP-1, in addition to a nine-residue C-terminal extension which is absent in GLP-1 peptide (Figure 1 ). Furthermore, exendin-4 retains its strong helicity at its Nterminal (from residues 11 to 27) due to the presence of helix-favouring glutamate residue at position 16 (Glu16), which is not found in the GLP-1 peptide. 18 Meanwhile, the remaining residues in exendin-4 acquire a disordered and segmental motion. The alpha-helix is the predominant structure in exendin-4 ( Figure 2) . A compact tertiary fold at C-terminal, known as tryptophan (Trp) cage, is formed between Leu21 and Pro38 and allows the tattering of helicity in exendin-4 to occur exclusively from its N-terminal sequences. It is clearly articulated that interaction between exendin-4 and GLP-1 receptor is responsible for the downstream activation of cAMP-mediated glucose-dependent insulin secretion. The GLP-1 receptor is the cellular target of exendin-4. The receptor belongs to Family B secretion G protein-coupled receptor (GPCR) and comprises N-terminal extracellular domain and a transmembrane core domain. 19 The receptor has a large N-terminal extracellular ligand binding domain. A typical class B GPCR family activation mechanism can be explained by a two-domain model involving an N-terminal domain (NTD) extracellular site for agonist binding and a transmembrane (TM) core domain for second messenger signal transduction. 20 Thus, the activation of reveals that the NTD extracellular domain of the receptor consistently interacts with a peptide agonist for receptor activation. The hydrophobic residues within the extracellular domain maintain the tertiary structure of the NTD for precise binding to agonist peptide, whereas, the hydrogen bonding within the receptor maintains the three-dimensional structure of the receptor. There are four crucial residues on the receptor NTD, being Thr35, Ala70, Leu89 and Pro90, which maintain the functional affinity of exendin-4 in which Ala70 facilitates hydrophobic packing. 21 A few crystal structures of exendin peptide with GLP-1 receptor are available, for instance exendin 9-39 (PDB:3C59)-or exendin-4 variant (PDB:5OTT)-bound extracellular NTD of GLP-1 receptor. Nonetheless, a high-resolution structure of exendin-4-bound full-length GLP-1 receptor is not obtainable so far to illustrate the exact mode of interaction. Therefore, an in silico docking analysis of exendin-4 with full-length GLP-1 receptor was conducted in-house to illustrate the interaction. The key residues of exendin-4 interact with GLP-1 receptor are mapped, with the available literature data up to date (Figure 3) . The in silico docking analysis discloses that the N-terminal residues of exendin-4 are not involved in the interaction with GLP-1 receptor. Therefore, the N-terminal residues of exendin-4 do not contribute to the differential binding affinity towards GLP-1 receptor as compared to the GLP-1 peptide. Despite this, the residues in the helical region of exendin-4 and the C-terminal extension residues are responsible for the primary interaction with the extracellular NTD of GLP-1 receptor, 22 as illustrated in Figure 3 . The key residues of exendin-4 are Val19, Arg20, Phe22, Ile23, Trp25, Leu26, Lys27 (at helical region) and Gly30, Pro31, Ser32 and Ser39 (at C-terminal extension) which interact directly with extracellular NTD of GLP-1 receptor via hydrogen bonding and van der Waals interaction. Truncation of the N-terminal sequences up to eight amino acid residues has a negligible effect on the exendin-4 affinity for GLP-1 receptors. 23 However, truncation of a single amino acid residue from the N-terminal of the exendin peptide diminishes its agonistic properties.
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The nine-residue C-terminal extension of exendin-4 is responsible for the enhanced binding affinity with the NTD of the receptors, which is absent in the GLP-1 peptide. 22 This is because exendin-4 forms an additional interaction (ex-interaction) with the isolated NTD of the receptors, F I G U R E 2 The structure of exendin-4 was determined by the authors using MODELLER v9.20. Exendin-4 retains strong helical proclivity exclusively from the N-terminal, and a folded "Trp" cage is formed at C-terminal extension for the enhanced binding to GLP-1 receptor. Ramachandran plot analysis is used to visualise the polypeptide backbone at a different angle psi (ψ) against phi (φ) of amino acid residues. There is a tight grouping of amino acid residues at φ = −45 and ψ = -30 to -50, indicating that α-helix is the predominant secondary structure in exendin-4 F I G U R E 3 The overall structure of full-length human glucagon-like peptide 1 (GLP-1) receptor in complex with exendin-4 peptide. A, The ribbon representation of human GLP-1 receptor (blue colour, based on sequence P43220.2) and exendin-4 (green colour) constructed using ZDock. B, Molecular mapping of the key residues within exendin-4 involved in the interaction with the receptor's NTD. The residues mapping representation of exendin-4 in complex with NTD is displayed as surface square planar to better illustrate the key residues involved in the binding to the receptor's NTD. The key residues at helical region (Val19, Arg20, Phe22, Ile23, Trp25, Leu26, Lys27) and C-terminal extension (Gly30, Pro31, Ser32 and Ser39) of exendin-4. Based on the in silico docking analysis, the residues at helical region and C-terminal extension are responsible for the primary interaction with the receptor's NTD. The major intermolecular forces to maintain this complex are hydrogen bonds and van der Waals forces as determined by RING 2.0 (http://protein.bio.unipd.it/ring/). The C-terminal extension with Trp cage enhances the binding affinity to the receptor's NTD attributed to the presence of amino acids at position 9 to 39 which are not conserved in GLP-1. 16 The ex-interaction in exendin-4 allows its interaction with the receptor without requiring its N-terminal region. This extension segment of exendin-4 enables the peptide to acquire structural dynamic to be readily bound to the NTD site of the GLP-1 receptor. 22 Furthermore, increased helicity in exendin-4 is crucial for its high binding affinity towards the fully isolated NTD preparation. The differential affinity for exendin-4 and GLP-1 to the isolated NTD is ascribable to the Trp cage in exendin peptide as well as the divergent residues of the central part of the agonists (Leu10-Gly30 in exendin-4; Val16-Arg36 in that of GLP-1). 17 The presence of a Trp cage motif in exendin-4
further enhances the interaction with the isolated NTD. 16 The Trp cage in exendin-4 allows its C-terminal extension to interact with Phe80, Tyr101 and Phe103 of the receptor. 21 Such differential binding affinity is also related to the hydrogen-bonded polar core of the GLP-1 receptor. 22 However, the differential affinity of exendin-4 and GLP-1 is not observed in membrane-tethered human GLP-1 receptor (a full-length receptor with an N-terminal extracellular domain and transmembrane, TM core domain), as revealed by a competitive radioligand assay. 24 Exendin-4 appears to interact minimally with the NTD of the human GLP-1 receptor, in comparison with the GLP-1 peptide.
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Both exendin-4 and GLP-1 have a comparable binding affinity to the membrane-tethered GLP-1 receptor, presumably due to close proximity of cell membranes, which eliminate the differences in helical proclivities in both peptides. 24 It appears that the nine-residue C-terminal extension of exendin-4 peptide has no significant contribution to its binding affinity against the membrane-tethered human GLP-1 receptor. 17 In contrast, a differential binding affinity of exendin-4 and GLP-1 is observed in rat GLP-1 receptor. Exendin-4 displays higher binding affinity than GLP-1 for rat GLP-1 receptor and induces elevated intracellular cAMP levels as measured in a functional assay. 15 The helical proclivity of exendin-4 enables its better binding affinity to rat GLP-1 receptor. 24 Besides, the nine-residue C-terminal extension of exendin peptide is also responsible for such differential affinity. 22 This is because the Ser32 at the C-terminal extension (absent in GLP-1) of exendin peptide forms a hydrogen bond with Asp68 (which is found in NTD) of the rat GLP-1 receptor. This hydrogen bonding further intensifies the binding affinity of exendin-4 to rat GLP-1 receptor. On the contrary, in human GLP-1 receptor, such hydrogen bonding capability is fully diminished because Glu68 is present in the NTD of human GLP-1 receptor, instead of Asp68. 24 This explains the reason why human full-length GLP-1 receptor does not possess differential interaction, neither with GLP-1 nor with exendin-4, unlike in the case of rat GLP-1 receptor.
The helical proclivity and C-terminal extension with Trp cage are both crucial properties of exendin-4 for the binding to the NTD of GLP-1 receptor. A contemporary GPCR activation model involves not only the NTD but also the core domain at the transmembrane region of the receptor. Earlier studies have discovered the interaction sites in GLP-1 receptor core domain with GLP-1 peptide but not with that of exendin-4. 17, 25 Nonetheless, there are no structural data available for the binding of exendin peptide to the receptor core domain. It causes the exact activation mechanism of GLP-1 receptor by exendin-4 becomes unclear. Since exendin-4 does not show a discrepancy in the binding affinity for isolated NTD and full-length GLP-1 receptor, 23 it thus suggests that the core domain of GLP-1 receptor may not be crucial for stage two receptor activation. This is further proven when mutation or removal of the receptor's core domain has no detrimental impact on the binding of exendin peptide to GLP-1 receptor. 16, 22 As discussed above, the binding of exendin-4 to the receptor is primarily dependent on its helical proclivity and C-terminal extension.
Since a typical GPCR family activation involves an extracellular domain and transmembrane core domain, now the question arises how exendin-4 activates the GLP-1 receptor without it interacting directly with the core domain. The receptor activation involving core domain can be explained by a hypothesised model, known as the intrinsic agonist model. 26 The intrinsic agonist model suggests an endogenous mechanism of the core domain activation. It has been demonstrated that the GLP-1 receptor remains in its original closed apo-state when there is no ligand binding. 26 However, when exendin-4 binds to NTD extracellular domain of GLP-1 receptor, it might switch the receptor from an auto-inhibited state to an auto-activated state. 26 The NTD extracellular domain retains its close proximity with the core domain as "stay down" manner, after ligand binding. The exendin-4 presumably behaves as an allosteric modulator of the NTD conformation to allow its in-depth interaction with the core domain and thereby activates the receptor. 26 In addition, a short and non-specific peptide linker (EFGSA) devoid of complete exendin-4 sequence is effective enough to activate the receptor, indicating that the N-terminal sequences of exendin-4 are dispensable for receptor activation. This proposes that the allosteric modulation of the NTD extracellular domain following ligand binding is accountable for the activation of the receptor's core domain. However, it is necessary to experimentally elucidate a high-resolution crystal structure of exendin-4 peptide-bound fulllength GLP-1 receptor, for example by X-ray crystallography. It will further ascertain the role of core domain in the activation of GLP-1 receptor to explore its underlying mechanisms behind the receptor activation. -induced exocytosis of insulin-containing vesicles to facilitate secretion of insulin. The activation of GLP-1 receptor causes an enhanced glucose-dependent insulin secretion from pancreatic β-cells, in addition to the inhibition of inappropriate glucagon secretion. 28 This promotes glucose uptake when the plasma glucose levels are high, especially after an oral glucose load such as food ingestion or parenteral injection of glucose. Exendin-4 is equally potent at activating the mammalian GLP-1 receptor as endogenous GLP-1 itself. 13 It activates GLP-1 receptor and elicits an insulinotropic effect when the plasma glucose levels are high 29 ( Figure 4 ).
Besides, exendin-4 is 10 times more potent than GLP-1 in the differentiation of AE42J cells (pancreatic precursor cells) into insulin and glucagon-islet cells. 30 Furthermore, exendin-4 is more stable against enzymatic degradation by dipeptidyl-peptidase (DDP-4) as compared to endogenous GLP-1, resulting in a longer biological half-life and producing a prolonged effect with substantially lower blood glucose levels. 31 Therefore, exendin-4 offers a better therapeutic option for T2DM as compared to GLP-1.
| Cytoprotection of pancreatic β-cells and insulinotropic effect of exendin-4
Type II diabetes mellitus is manifested by chronic insulin resistance or malfunction of β-cells resulting in impaired insulin secretion. Exendin-4 activates GLP-1 receptor and stimulates the secretion of insulin to promote the glucose uptake in muscle and adipocytes via phosphoinositol 3-kinase signalling pathway ( Figure 4 ). The insulinotropic effect of exendin-4 is also related to its antagonistic action against glucagon, thus promoting glucose-dependent insulin release. Exendin-4 could also stimulate counter-regulatory responses during hypoglycaemia stage. 32 An in vitro study using 50 isolated pancreatic Islet of Langerhans from male Lewis rats as a control, were perfused with HBSS buffer containing 3 mmol/L of glucose before treatment with 20 nmol/L exendin-4 and GLP-1. 29 The finding showed that a 7-10 times increase in the secretion of insulin was observed in the exendin-4-treated groups. A concurrent study was conducted using in vivo male Lewis rats that were intravenously infused with exendin-4 and showing a maximum insulinotropic effect from 30 to 90 minutes. after infusion. The in vivo insulinotropic effects of exendin-4 are also extrapolated in T2DM patients. The therapeutic doses of exendin-4 in T2DM patients increased by 3 times the time taken for 50% stomach emptying. 33 As reported by Egan and colleagues in 2002, 34 exendin-4 also triggers glucose-dependent insulin secretion in T2DM patients, thereby suppressing the secretion of glucagon in a dose-dependent manner without delaying gastric emptying. The insulin levels remained high for several hours in blood, even after withdrawal of exendin-4. Besides, a number of studies have revealed the role of exendin-4 in promoting the proliferation and neogenesis of pancreatic β-cells. Exendin-4 is found to increase the mass of β-cell islets and thus promotes insulin secretion. 35 The proliferation of β-cells is more likely mediated by epidermal growth factor receptor (EGFR) and Wnt5a pathway. 36, 37 On the other hand, exendin-4 also promotes the expression of insulin receptor substrate 2 (Irs2) and stimulates Akt phosphorylation leading to proliferation of β-cells by 2 times. 38 This causes a delayed progression of hyperglycaemia and a significantly reduced level of glycated haemoglobin A1c (HbA1c), a biomarker for mean plasma glucose levels. 39 In addition, exendin-4 exhibits cytoprotective effects on β-cells to avoid unnecessary cell death. For example, exendin-4 suppresses CXCL10 gene-associated dysfunctions in human MIN6 pancreatic β-cells through MAP3 kinase pathway. 40 On the other hand, exendin-4 also possesses a protective effect against tert-butyl hydroperoxide (t-BHP)-induced apoptosis in murine MIN6 pancreatic β-cells. This cytoprotective effect is mediated by substantially diminished caspase-3 activity, inhibition of endoplasmic reticulum transmembrane protein (IRE1) and suppression of apoptotic mediators such as JNK and c-Jun. 41, 42 Furthermore, exendin-4 protects the β-cells' mitochondria from the detrimental effects of reactive oxygen species. 43 The antioxidant mechanisms of exendin-4 are attributed to its agonistic action on GLP-1 receptor via elevation of intracellular cAMP levels, followed by activation of Epac-dependent signalling pathways which up-regulate the expression of antioxidant enzymes such as catalase and glutathione peroxidase. 44 The cytoprotection mechanisms of β-cells and insulinotropic effects of exendin-4 are summarised in Figure 4 .
| Pharmacology of exendin-4 in type II diabetes mellitus (T2DM)
Diabetic neuropathy and nephropathy are both critical complications in diabetic patients. Exendin-4 prevents diabetic neuropathy with pronounced neuroprotective effects. In exendin-4-treated diabetic rats, there is an observable increase in the GLP-1 receptor expression, followed by a reduction in myelinated fibre size of the sciatic nerve. 45 The loss of intraepidermal nerve fibre in the skin of diabetic rats was successfully ameliorated. The neuroprotective effects are likely to link to the anti-apoptotic action and restoration of cAMP levels in the presence of exendin-4. 45 Besides, neuroprotective effects of exendin-4 prevent impairment of cognitive functions in T2DM through modulation of inflammation, attenuation of oxidative stress and maintenance of normal synaptic function. This is due to the anti-apoptotic role of exendin-4 in rescuing brain tissues through activation of phosphoinositol 3-kinase (PI3K)/ Akt signalling pathway, down-regulation of caspase and elevation of Bcl-2 levels. 46 Exendin-4 is also potentially
The biological effects of exendin-4 following activation of glucagon-like peptide 1 (GLP-1) receptor in pancreatic β-cells. Such effects include glucose-dependent insulin secretion, cytoprotection and regulation of β-cells proliferation for normal physiological functions. Exendin-4 binds to GLP-1 receptor, stimulates adenylyl cyclase (AC) and causes an elevation of intracellular cAMP levels. This leads to activation of protein kinase A (PKA) and Epac (exchange protein activated by cAMP). Lower levels of cAMP induce preferential activation of PKA, but Epac becomes more sensitive to cAMP when PKA is saturated. This is essential for the regulation of insulin secretion and cells cycle. It has been suggested that activation of incretin receptor in response to high blood glucose levels causes metabolism of glucose to produce ATP. The glucose uptake into β-cells is mediated by glucose transporter 2 (GLUT2). The ATP is essentially used for activation of ATP-sensitive potassium ion channel (K ATP channels), for depolarisation of cell membranes allowing Ca 2+ influx via voltage-gated Ca 2+ channel. At the same time, Epac is involved in the release of Ca 2+ from endoplasmic reticulum (ER). Ca 2+ then stimulates insulin secretion from β-cells by an exocytosis of the insulin secretory vesicles. Besides, Ca 2+ also activates Ca 2+ /Calmodulin kinase, which recruits transcription complex NAFT that leads to an expression of insulin genes. The secreted insulin promotes high rates of glucose uptake into adipocytes and muscle cells via a glucose transporter 4 (GLUT4). Activation of GLP-1 receptor by exendin-4 also increase the gene expression of insulin receptor substrate 2 (IRS2), followed by activation of PI3 kinase/Akt pathway. Stimulation of Akt phosphorylation suppresses apoptosis of beta cells via down-regulation of caspase enzyme and elevation of BCl-2. On the other hand, exendin-4 action also increases expression of cyclin D1 via EGFR-mediated Wnt5a pathway, which increases the cell proliferation and inhibit apoptotic pathways in β-cells. Epac is also involved in up-regulation of the genes encoded for antioxidant enzymes such as glutathione peroxidase (GPX) and catalase to ameliorate reactive oxygen species in β-cells. Exendin-4 suppresses CXCL10 gene-associated dysfunctions in pancreatic β-cells through MAP3 kinase pathway. This is achieved by inhibition of ER transmembrane protein (IRE1). Inactivation of MAPK also reduces the synthesis of cytokines and cyclooxygenase-2 (COX-2). Altogether, exendin-4 exhibits anti-inflammatory roles and possesses cytoprotective effects for β-cells
ameliorating diabetic nephropathy and diabetic-induced renal fibrosis. As observed in exendin-4-treated db/db mice, there was a significant reduction in urinary albumin excretion associated with glomerular hypertrophy, expansion of the mesangial matrix and expression of growth factor TGF-β1. There was also less appearance of inflammatory and apoptotic cells in the glomeruli of treated db/db mice. 47 This is attributed to the capability of exendin-4 in combatting the endogenous oxidative stress by restoring antioxidant levels 48 as well as down-regulation of miR-192 from damaged kidney tubular epithelial cells. 49 The nephroprotective effects of exendin-4 are also linked to upregulation of ATP-binding cassette transporter A1 (ABCA1) in glomerular endothelial cells. 50 Other than the therapeutic effects for diabetic complications as discussed earlier, exendin-4 has wound-healing properties as well, attributed to its anti-inflammatory properties. The anti-inflammatory properties of exendin-4 successfully attenuate inflammatory mediators such as IL-1β, TNF-α and IFN-γ. It increases circulating endothelial progenitor cells for the capillary tube formation and activates transforming growth factor-β/matrix metalloproteinase as well as promoting angiogenesis. 51 Since oxidative stress appears to be the contributing factors for cellular damage such as neuronal cells, renal glomerular epithelial cells and pancreatic β-cells in diabetic patients, the above findings support the role of exendin-4 as free-radical scavengers by restoring the normal redox homeostasis. Furthermore, it enhances normal osteoblastic differentiation in periodontal ligament stem cells (PDLSCs) by attenuation of ROS. 52 Exendin-4 possesses the cardioprotective function as it improves coronary endothelial functions in T2DM patients. It helps reduce the levels of soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) and reactive oxygen species (ROS). Exendin-4 also increases the synthesis of nitric oxide by stimulating the enzyme endothelial nitric oxide synthase (eNOS). 53 On the other hand, exendin-4 exhibits anorexigenic effects on the mesolimbic reward system involving a central GLP-1 receptor and sensory afferent pathway. 54 The anorexigenic effects are crucial in food intake, appetite control and weight gain and the contributing factors to oral glucose loads. In an in vivo study using mice models, exendin-4 was found to cause a reduction in food intake, net weight loss and inhibition of gastric emptying as well as enhanced secretion of glucagon. 55 In another study using ob/ob mice treated with exendin-4 at 10 μg/kg or 20 μg/kg for 60 days, there was a significant decline in body-weight, plasma glucose levels and oxidative stress followed by an improved insulin sensitivity and lipid metabolism. Similar effects were also observed in Zucker fatty rats treated with exendin-4, including an acute decrease in food intake. 56 On the other hand, exendin-4 could also attenuate postprandial hyperglycaemia by minimising the endogenous gluconeogenesis by up to 50% and encourage a delay in gastric emptying. 57 
| Other therapeutic applications of exendin-4
The neuroprotective properties of exendin-4 enable exploration of its additional therapeutic potency in neurodegeneration disorders. A preclinical study revealed that exendin-4 is able to prevent degenerative disorder in Alzheimer's disease. Exendin-4 protects the rat model against amyloid beta (Aβ 1-42)-induced cognitive behavioural impairment 58 in a dose-dependent manner. This is mediated by increased expression of BCl-2 and down-regulation of caspase-3. Besides, exendin-4 is also found to be an effective therapeutic option for Parkinson's disease. In the most recent study by Chen and colleagues, 59 post-administration of exendin-4 was found to elevate the level of tyrosine hydroxylase in substantia nigra and striatum. Tyrosine hydroxylase is a key enzyme for the formation of L-Dopa, which is the rate-limiting biosynthesis step of dopamine. Exendin-4 also reduces the neurodegeneration of dopaminergic neurons in the 6-hydroxydopamine rate model. 59 The clinical trials for exendin-4 as a novel therapeutic drug in Alzheimer's and Parkinson's disease are in progress. Besides, the activation of downstream effector signalling cascades following of GLP-1 receptor by exendin-4 enables the extrapolation to potentially target cancer signalling pathways. For example, exendin-4 inhibits GLP-1 receptormediated extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) pathway, resulting in a remarkable impediment of prostate cancer growth. 60 In addition, exendin-4 suppresses proliferation and metastasis of ovarian cancer cells in nude mice models through apoptosis and inhibition of PI3K/Akt pathway. 61 Last but not least, development of new fluorochrome compounds based on exendin-4 is essential for rapid β-cells analysis, for instance, in vivo imaging using flow cytometry and microscopy in basic and translational β-cells research. 62 Moreover, it provokes an additional possibility for such exendin-based fluorochrome as a diagnostic tool for detection of abnormalities in β -cells.
| PHARMACOKINETICS OF EXENDIN-4

| Pharmacokinetics of exendin-4 in animals
Pharmacokinetics of exendin-4 has been studied in animal models via different routes of administration. Most of the animal models used are rodents, either healthy or diabetic/ obese rats. The pharmacokinetics of exendin-4 in experimental animal models differs greatly according to the route of administration and administered dose. Table 1 summarises the pharmacokinetic parameters of exendin-4 in animal models. The subcutaneous (s.c.) administration of exendin-4 exhibits a better bioavailability compared to oral ingestion (Table 1) . This is because when exendin-4 is ingested orally, it is absorbed via intestinal epithelial cells and enters the hepatic portal system which can be metabolised by the enzyme peptidases in liver. 63 The first-pass effects of oral ingestion reduce the bioavailability of exendin-4. However, based on intravenous (i.v.) administration in animal models, exendin-4 has a shorter biological halflife compared to the s.c. route (Table 1 ). This suggests that s.c. is an ideal route of administration for exendin-4. Therefore, exendin-4 is parenterally administered via s.c. injection for therapeutic purposes in human volunteers.
| Pharmacokinetics of exendin-4 in human volunteers
To date, there are two different formulations of exendin-4 for therapeutic uses, namely Exenatide QW and Exenatide BID. Exenatide BID is a fast-acting exendin-4 for twicedaily administration while Exenatide QW is an extendedrelease, long-acting preparation of exendin-4 for onceweekly injection. Exenatide QW contains the same active exendin-4 encapsulated into biodegradable hydrogel microspheres of poly(D,L-lactide-co-glycolide) for an extended duration and sustained release of exendin-4 64 for therapeutic purposes. Their pharmacokinetic properties are different, especially in the absorption phase whereby the absorption rate of exenatide BID follows zero-order kinetics for immediate release of exendin-4 from the preparation. 65 On the other hand, exenatide QW exhibits first-order rate in the absorption process indicating a rapid initial release. 66 The initial release of exendin-4 in Exenatide QW lasts for 48 hours, followed by diffusion lasting for 2 weeks and finally an erosion release which lasts for 7 weeks. 66 This active peptide is thus administered on a weekly basis to sustain its bioavailability. In a population pharmacokinetics study of exenatide QW in 64 patients, the patients received a single dose (either 2.5, 5, 7 or 10 mg) and multiple doses (either 0.8 and 2 mg) for 15 weeks, revealing a steady level of exendin-4 in diabetic patients for 8-10 weeks. 66 In human volunteers, exendin-4 has a median volume of distribution (V D ) 28 L (Table 2 ) demonstrating a good distribution whereby exendin-4 does not remain in the plasma; instead, it is well distributed to GLP-1 receptors at pancreatic β-cells. The s.c. administration of fast-acting exendin-4 is usually followed by a sharp elevation of its concentration in the plasma, with a maximum time (T max ) of 2-3 hours after administration (Table 2) , while the peak concentration of exendin-4 in plasma (C max ) is achieved approximately 2 hours after administration ( Table 2 ). The C max of exendin-4 falls within a concentration range of 193-220 pg/mL for a single dose of 10 μg, whereas a single dose of 2.5 μg and 5 μg of exendin-4 results in C max values of 56 pg/mL and 85 pg/mL, respectively (Table 2) , suggesting a dosedependent absorption manner. The s.c. administration of exendin-4 in human volunteers recorded a bioavailability of 93%-97%, indicating that this route of administration is ideal for the therapeutic purpose (Table 2) . On the other hand, the bioavailability of exendin-4 in animals falls between 51% and 75% (Table 1) . Several clinical reports have reported the pharmacokinetic parameters of fast-release or extended-release exendin-4. The pharmacokinetic parameters of exendin-4 reported by several clinical studies are summarised in Table 2 . Most of the reported pharmacokinetic values reflect the pharmacokinetic properties of exendin-4 in T2DM patients, and it is notable that the biological half-life of exendin-4 is up to 4 hours only. Exendin-4 is not susceptible to enzymatic degradation by dipeptidyl-peptidase 4 (DPP-4), unlike the endogenous GLP-1. This extends its plasma half-life for prolonged incretin actions, in comparison with GLP-1. Passive glomerular filtration is the primary route of renal elimination for exendin-4. 67 The enzymes responsible for the proteolytic actions of exendin-4 are metalloproteases, aminopeptidases and serine proteases. 63 The in vitro data also suggest that the breakdown of exendin-4 in the liver first occurs through the actions of endopeptidases before being further excised by exopeptidases. 63 The main peptide fragments produced from the proteolytic degradation of exendin-4 are inactive metabolites indicates that they neither act as agonists nor antagonists of the GLP-1 receptor.
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Since exendin-4 has been shown to possess delayed gastric emptying effects, drug-drug interactions may occur to alter the pharmacokinetics of the concomitantly administered drugs. In a pharmacokinetic study reported by Blase et al, 68 the presence of acetaminophen reduced the absorption rate of exendin-4 with lower C max value and longer T max , but the total exposure of exendin-4 (based on the AUC value) was not affected. Similar findings have also been documented in concomitant administration of exendin-4 with warfarin, digoxin and lovastatin whereby a decline in total exposure was observed for lovastatin. [69] [70] [71] Thus, it requires extra attention when exendin-4 is co-administered with other drugs; especially, the drugs narrow therapeutic indexes such as warfarin and digoxin.
| CHALLENGES OF EXENDIN-4 AS ANTI-DIABETIC DRUG
To date, the existing therapeutic protocol for exendin-4 uses Byetta ® pen injection of the active peptides via a subcutaneous route. Nevertheless, one of the drawbacks for exendin-4 as an anti-diabetic drug is always attributed to its short biological half-life (1-4 hours). In order to maintain the therapeutic levels of exendin-4, patients are required to receive the subcutaneous dose twice daily, which may lead to failure in patients' compliance due to pain and inconvenience of self-injection. Extended-release Exenatide QW is thus formulated for sustained release of exendin-4, allowing weekly administration of exendin peptide rather than routine daily regimen. Since there is no T A B L E 2 Pharmacokinetics parameters of exendin-4 in healthy volunteers and patients of type II diabetes mellitus (T2DM)
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s.c. generic alternative, the existing therapeutic protocol is way more expensive. Moreover, the risk of infections could increase when patients rely on subcutaneous injection of exendin-4. It prompts to an urgency to explore alternative routes of drug administration besides subcutaneous route, but also to consider bioavailability of exendin-4 in other routes of drug delivery.
| Modification of exendin-4 to improve bioavailability
Several modification approaches are attempted to increase the bioavailability of exendin-4 to be stably delivered to β-cells. The analogue of exendin-4 with improved helicity is named E19 and comprises the same peptide length with structural similarity to exendin-4, but appears to be more helical than exendin-4. 72 In some circumstances, exendin-4 has poor hydrophilicity resulting in the formation of aggregates incapable of interacting with GLP-1 receptors for responses, thus reducing its bioavailability (usually animal F is 50%-70%, Table 1 ; human F is 93%-97%, Table 2 ). The E19 analogue possesses a folded "Trp cage" to prevent helix-helix interaction with better folding stability and water solubility. This well-folded "Trp cage" is introduced to E19 analogue through a step-by-step elongation of the "Trp cage" head from the parent 20 amino acid residues. 72 Although an increase in water solubility of E19 leads to better bioavailability, the exact bioavailability of E19 is yet to be confirmed.
| Modification of exendin-4 pharmacophore by protein engineering
Chronic exposure of GLP-1 receptor to exendin-4 causes receptor sensitisation (an enhancement of the responses resulting from GLP-1 receptor activation following repeated and prolonged exposure to exendin-4) and overexpression of cyclin D1, leading to pro-proliferation of pancreatic β-cells. 73 It prompts the matter to reconceive the pharmacophore of exendin-4 to halt the prolonged sensitisation of the receptor. Modification to the existing exendin-4 has been undertaken to alter the pharmacophore of exendin-4. For example, a short stretch of glucagon sequence is integrated to exendin-4 to design a novel glucagon-exendin fusion protein. This fusion protein exhibits a dual co-agonism with significant effects on better lowering effect of glucose levels and weight loss, compared to pure exendin-4. 74 It helps to switch single receptor activity to dual activity with an equilibrium of the relative GLP-1/glucagon receptor activity ratio. This diversifies the agonism of exendin peptide, not restricting to just GLP-1 receptor but also glucagon receptor, and it helps prevent prolonged receptor sensitisation.
| Modification of exendin-4 to improve the biological half-life of exendin-4
The biological half-life of exendin-4 is prolonged by substitution of its amino acid at position 20 or 38 through acylation of lysine residues with carboxylic acid. A residue substitution of Gln28 for Asn28 in exendin-4 potentially increases its action without degradation after subcutaneous administration. 75 This variant of exendin-4 demonstrates a better stability and longer half-life with no effects on its pharmacology in rodents, which is suitable for a oncemonthly regimen.
Other attempts to increase the half-life of exendin-4 are by PEGylation, an amalgamation process of polyethylene glycol (PEG) to exendin-4 that reduces the degradation rate by metabolic enzymes and reducing immunogenicity. 76 This is achievable by replacing the Cys-39 with PB-105, providing a free thiol group readily for a conjugation. Other modifications of existing exendin-4 can also be achieved by the conjugation of exogenous molecules to the incretin peptide. For example, a conjugation with maleimide derivatives of Evans blue dye produces an exendin peptide with longer half-life and better hypoglycaemic effects. 77 Another example is the conjugation of fatty acids with lysine residues of exendin-4 to form a sterically stable micelle for an extensive absorption. 78 On the other hand, conjugation of exendin-4 to IgG Fc was found to have extended biological half-life for long-term glucose regulation in diabetic mice in a dose-dependent manner. 79 6.4 | Modification to the formulation of exendin-4 to alter the route of administration
Researchers have also opted for a new exendin-4 analogue with other routes of administration with a better bioavailability, potency and more convenient for patients. One example is pulmonary inhalation, which allows drugs with limited oral bioavailability to enter more readily into systemic circulation. This is because the lung has a large surface area and it is highly perfused with blood. It provides a better absorption of the drugs with higher bioavailability. The particle size of the formulation is the fundamental features for the drugs to be delivered via inhalation. 80 Drugs must first be converted into simpler particles with excipients or surfactants that can be formulated into nebulisers or inhalers. In a modification attempt by Kim et al, 81 the researchers constructed a new prototype of a porous microsphere comprising poly(lactic-co-glycolic acid) PLGA coated with palmityl-acetylated exendin-4, a fatty acidmodified exendin-4 analogue. The findings showed that the modified analogue was a sustained release formulation and possessed an efficient absorption through the lung with more pronounced hypoglycaemic effects. This PLGA- palmityl-conjugated exendin-4 was further improved for its half-life by coating the surface of the particles with a glycol chitosan. 82 The encapsulated peptide can also be formulated in a microscopic needle for minimal invasive injection into the skin. 83 Although oral administration of exendin-4 is less likely used as one of the delivery options due to first-pass effects, oral ingestion is still the most convenient way for drug administration for better patient compliance. Therefore, a new exendin-4 analogue, Trypsin Cleavage Site Mutated Exendin-4-Cysteine 1 (TSME-1), has been designed with similar biological activity with exendin-4, but completely resistant to trypsin digestion and having higher bioavailability than that of exendin-4. 84 The modifications of existing exendin-4 suggest the new exendin-4 analogue as a potential therapeutic candidate for T2DM in the future.
| CONCLUSION AND FUTURE
DIRECTIONS
The discovery and isolation of exendin-4 from H. suspectum venom has resulted in the further development of this small incretin-mimetic peptide as one of the therapeutic options for T2DM. Due to the fact that it is resistant to enzymatic degradation by dipeptidyl peptidase, it has been used as a potent drug for T2DM. To date, the synthesized form of exendin-4 is commercialised in two formulations, namely Exenatide QW and Exenatide BID, either in Byetta ® or Bydureon ® . Nonetheless, there is currently no generic equivalent version of Byetta ® available, making it a costly product. Exendin-4 rescues normal physiological functions of pancreatic β-cells to elicit glucose-dependent insulin secretion. The structural properties of exendin peptide explain its better agonistic effect on the GLP-1 receptor, as compared to the endogenous GLP-1 peptide. It adopts a two-domain binding mechanism, the C-terminal extension containing Trp cage further enhancing its binding affinity. After binding of the receptor to NTD, it acts as an allosteric modulator, enabling the extracellular NTD to acquire close contact to the core domain of GLP-1 receptor for signal transduction. However, there are no structural data available about the receptor core domain, and the crystal structure of the exendin-bound receptor complex is not fully elucidated. It is essential to determine the crystal structure of exendin-bound GLP-1 receptor to clearly indicate the pharmacophore for future modification of exendin-4 with better efficacy and potency.
Subcutaneous injection appears to be the primary route of delivery for exendin-4 with a bioavailability >93% in human volunteers. However, it has relatively shorter plasma halflife, thus requiring a repeated dosing regimen to maintain the therapeutic levels. One of the main challenges encountered during therapeutic application of exendin-4 is patient compliance when using self-injection pen which may lead to possible risk of infections. Different modification approaches are attempted to improve its pharmacophore characteristics and pharmacokinetics with different routes of administration. This includes structural alteration by amino acid substitution, conjugation with different molecules, encapsulation or coating of exendin peptide with microporous materials. Although preclinical assessments of the modified exendin-4 analogues demonstrate added therapeutic values to exendin-4, demonstrated clinical data are still lacking in human volunteers. The development of new formulations certainly requires establishment of the efficacy, potency, safety and the pharmacokinetic properties. Artificial intelligence (AI) platform can be incorporated for more precise prediction of the pharmacophore properties of exendin-4, enabling development of precise anti-diabetic medicine. Furthermore, it allows better and organized collation of big data such as data of clinical trials and adverse drug effects. This is a faster, more effective and cheaper approach for future drug modification, and encourages development of generic exendin at an affordable cost.
